Konu "treatment response" için Tıp Fakültesi Koleksiyonu listeleme
Toplam kayıt 6, listelenen: 1-6
-
Arthroscopic synovectomy in the treatment of functional ankle instability: Outcomes and gait analysis
(Springer-Verlag France, 2015)Background Natural consequence of repetitive ankle sprains is the chronic ankle instability. Objective of this study was to clarify the gait patterns of functional ankle instability (FAI) patients after arthroscopic ... -
Early shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization
(International Journal of Ophthalmology (c/o Editorial Office), 2017)AIM: To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period. METHOD: Thirty-eight patients with wet type age related macular degeneration(W-AMD) ... -
Empiric 131I treatment of high thyroglobulin levels in differentiated thyroid carcinoma after remnant ablation
(Acta Medica Mediterranea, 2014)Aim: The objective of this study is to establish the efficacy of empiric I-131 treatment (EIT) given for patients whose thyroglobulin(Tg) levels remained high after ablative I-131 treatment (AIT). Methods: Fifty-six patients ... -
Evaluation of Interictal Electroencephalography Findings in Patients with Focal Epilepsy: Does Secondary Bilateral Synchrony Play a Role on Seizure Frequency?
(Kare Publ, 2020)Objectives: Interictal electroencephalography (EEG) is an electrophysiological test used in daily practice and important in the diagnosis and treatment process for epileptic patients. Accurate assessment of the interictal ... -
The first case of Henoch-Schönlein purpura associated with rosuvastatin: Colonic involvement coexisting with small intestine
(BMJ Publishing Group, 2014)Henoch-Schönlein purpura (HSP) is a systemic vasculitis affecting small vessels. It is the most common systemic vasculitis in children, and is rare in adults. Serious gastrointestinal complications are more common in ... -
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
(Elsevier Inc., 2022)Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib ...